Evidence Hub

Combination of metformin and empagliflozin CAN changes GUT microbiota of type 2 diabetic patients with hypothyroidism and coronary artery disease

Kh.A. Moskva, O.P. Kikhtyak, LubovYevhenivna Lapovets

SCIENTIFIC PRACTICE: MODERN AND CLASSICAL RESEARCH METHODS, 2022

Abstract

Background and aims: Recently, the secrets of the effects of intestinal microbiota on the human body are gradually being revealed, but data are still insufficient. Considering the complexity of comorbid pathologies such as diabetes and hypothyroidism, which are often accompanied by the heart disease, it is necessary to detect changes in the state of the microbiota under the influence of Sodium-glucose cotransporter type 2 inhibitors (SGLT2i), metformin and levothyroxin. SGLT2i reduces cardiovascular morbidity and mortality, probably by increasing ketogenesis wich may influence on gut microbiome. There are studies that show increasing of Lactobacillales and decreased phylum Bacteroidetes in patients with established coronary artery disease (CAD). The aim of this study was to evaluate Firmicutes, Bacteroidetes, Actinobacteria, Lactobacilus spp., Bacteroidetes fragilis, Bacteroidetes thetaiotaomicron, Akkermansia muciniphila and Firmicutes/Bacteroidetes ratio in naïve type 2 diabetic patients with hypothyroidism and CAD before and after treatment.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free